First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Colorectal cancer vaccine (Primary) ; Tislelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms MYPHISMO
- 31 Aug 2018 Biomarkers information updated
- 26 Mar 2018 Planned initiation date changed from 30 Mar 2018 to 30 May 2018.
- 29 Jan 2018 New trial record